BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry... Show more
BLFS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 38 cases where BLFS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on October 03, 2025. You may want to consider a long position or call options on BLFS as a result. In of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BLFS just turned positive on October 03, 2025. Looking at past instances where BLFS's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
The 50-day moving average for BLFS moved above the 200-day moving average on October 01, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BLFS advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 201 cases where BLFS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for BLFS moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLFS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BLFS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.670) is normal, around the industry mean (10.969). P/E Ratio (0.000) is within average values for comparable stocks, (54.450). BLFS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.741). BLFS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (13.351) is also within normal values, averaging (14.774).
a manufacturer of proprietary and generic bio preservation media products for cells, tissues and organs
Industry PharmaceuticalsOther
A.I.dvisor indicates that over the last year, BLFS has been loosely correlated with RGEN. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BLFS jumps, then RGEN could also see price increases.
Ticker / NAME | Correlation To BLFS | 1D Price Change % | ||
---|---|---|---|---|
BLFS | 100% | +2.62% | ||
RGEN - BLFS | 59% Loosely correlated | +2.41% | ||
RVTY - BLFS | 51% Loosely correlated | +2.83% | ||
A - BLFS | 50% Loosely correlated | +2.12% | ||
DHR - BLFS | 47% Loosely correlated | +2.22% | ||
ITGR - BLFS | 46% Loosely correlated | +1.89% | ||
More |
Ticker / NAME | Correlation To BLFS | 1D Price Change % |
---|---|---|
BLFS | 100% | +2.62% |
Pharmaceuticals category (386 stocks) | 45% Loosely correlated | +0.12% |
Pharmaceuticals: Other category (103 stocks) | 41% Loosely correlated | +0.41% |